Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
April 28, 2014

Volcano commences limited market release of SyncVision

Manufacturer of precision-guided therapy tools Volcano has initiated the limited market release of its US Food and Drug Administration (FDA) cleared and CE Marked SyncVision technology system in the US and Europe.

Manufacturer of precision-guided therapy tools Volcano has initiated the limited market release of its US Food and Drug Administration (FDA) cleared and CE Marked SyncVision technology system in the US and Europe.

An online image processing workstation, SyncVision technology system is designed for coronary catheterisations.

Using this technology, the physician can navigate simultaneously on an angiogram and correlate significant IVUS findings with the corresponding spots using co-registration of the Eagle Eye Platinum catheter with x-ray angiography.

SyncVision provides the detailed vessel, lumen and wall structure from angiography and the spatial localisation of Volcano’s intravascular ultrasound images within the coronary tree together in a co-registered view to facilitate more informed treatment decisions and more efficient, enhanced workflow performance.

"It also allows for simple and precise length measurements to help inform stent selection."

University of Washington Medical Center director of cardiac catheterisation laboratory Dr Steven Goldberg said SyncVision allows correlation of significant IVUS findings with the corresponding spots on the angiogram.

"This addresses a challenging aspect of current practice in that it can be difficult to identify the precise spot needing treatment in translating the IVUS findings to the angiogram," Dr Goldberg said.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

"It also allows for simple and precise length measurements to help inform stent selection. Co-registration of different imaging modalities is currently the wave in interventional cardiology, and I think this is one of the most useful and user friendly co-registration formats I have seen. I believe that this truly represents the next generation in IVUS imaging."

While SyncVision is currently installed in multiple limited market release sites throughout the US and Europe, the company anticipates the full market release in later 2014.

The company is planning to share the SyncVision technology with a global audience next month at the EuroPCR meeting in Paris.

Volcano president and CEO Scott Huennekens said: "This system further bolsters our portfolio of recent innovative releases with the iFR modality, CORE Precision-Guided System, and CORE Control Pad, all of which work to help improve patient outcomes and customer productivity."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU